Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|June 14, 2019
SenzaGen Gains First Patent for GARDpotency
Author(s)Pharmaceutical Technology Editors
SenzaGen has revealed that is has been granted a patent in Europe for GARDpotency, a testing application that enables the measurement of the allergenicity of chemical substances without animal research.
Advertisement
Swedish-based company, SenzaGen, has revealed that is has been granted a patent in Europe for GARDpotency, a testing application that enables the measurement of the allergenicity of chemical substances without animal research.
“Getting this patent approved for the European market is commercially interesting, as there is a ban within the European Union on the sale of animal-tested cosmetic products,” said Anki Malmborg Hager, CEO of SenzaGen, in a June 13, 2019 press statement. “Furthermore, to quantify how strong the allergenic effect is according to classification and labeling (CLP/GHS) is a requirement in the EU chemical regulation REACH [Registration, Evaluation, Authorization, and Restriction of Chemicals]. As the only company in the world, SenzaGen can now offer an animal-free test method for this.”
The company’s GARD portfolio of products comprises a set of allergy tests that are performed on human cells in-vitroin combination with artificial intelligence, which can be used to replace animal testing in various industries, including pharma. There are several other ongoing patent applications for GARDpotency and other products in the portfolio.
Source:
Advertisement
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement